Login to Access Video or Poster Abstract: MP70-13
Sources of Funding: None

Introduction

Our objective is to report local disease control after primary whole gland cryoablation when used to treat Gleason ≥ 7 localized prostate cancers at our institution.

Methods

We analyzed 134 prostate cryoablation patients who had a Gleason score of ≥ 7 who underwent primary whole gland cryoablation. Progression free survival (PFS) was defined according to Phoenix definition of PSA nadir +2 ng/ml. Among the biochemical failure (BF) patients, we assessed local disease control by postoperative prostate biopsy, pelvic MRI or CT. BS was used to assess metastatic disease. We defined local treatment failure by a positive post cryoablation prostate biopsy and/or MRI/CT scan findings suggesting local recurrence within the prostate.

Results

PFS was noted in 101 patients (75%) with median follow up time of 31.5 months. Among the 33 patients who showed BF, 3 patients did not have a metastatic workup. Of the remaining 30 patients, 15 (11.2% of treated patients) showed only local treatment failure as indicated by positive post cryoablation prostate biopsy and/or MRI/CT scan findings suggesting local recurrence within the prostatic gland. The other 15 patients (11.2%) showed metastatic disease with no evidence of local treatment failure. (Table 1)

Conclusions

Cryoablation is a successful primary treatment option for patients with intermediate/high grade prostate cancer. Up to half of patients who showed biochemical failure had good local disease control but had distant failure as evident by post cryoablation prostate biopsy and/or MRI/CT scans; this suggests patient selection failing to identify micro metastasis present at the time of treatment rather than local treatment failure.

Funding

None